Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NS-863 dose-finding trial in pulmonary hypertension associated with interstitial lung disease
2025-525115-16-00Phase 2Authorised
- Sponsor
- NS Pharma, Inc.
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial in pulmonary hypertension associated with interstitial lung disease (PH-ILD) comparing NS-863 with Placebo (2 arms). Primary endpoint: Change in pulmonary vascular resistance. Planned start Oct 2026; status: authorised.
02
Drugs
NS-863
03
Conditions
pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Beyond the preview
Go deeper on 2025-525115-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525115-16-00.